PDL Divests Another Business – Genmab Gets Antibody Facility For $240 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Danish firm adds capacity to produce clinical and commercial scale material for its pipeline.
You may also be interested in...
PDL Can’t Find Buyer, Plans More Cutbacks
Fourth-quarter numbers disappoint, but savings could brighten picture.
PDL Can’t Find Buyer, Plans More Cutbacks
Fourth-quarter numbers disappoint, but savings could brighten picture.
PDL Ditches Cardene, Other Heart Failure Meds As Part Of Restructuring Plan
In a surprise move, former ESP Pharma executive snaps assets back up from PDL at what some consider a bargain-basement price.